Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

OKN-007 i kombination med adjuverende temozolomid kemoradioterapi til nydiagnosticeret glioblastom

16. september 2026 opdateret af: University of Oklahoma

Feasibility Pilotundersøgelse af OKN-007 i kombination med adjuverende temozolomid kemoradioterapi hos patienter med nyligt diagnosticeret glioblastom

This is a pilot study exploring the potential benefit of adding OKN-007 with Temozolomide for treatment in patients with malignant Glioblastoma undergoing adjuvant concomitant radiotherapy. This drug combination is expected to have an anti-cancer effect in patients who have experienced disease progression after first line treatment.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

27

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73117
        • Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 99 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients have newly diagnosed histologically proven WHO grade III or grade IV Glioblastoma Multiforme (GBM).
  • Patients at initial presentation of GBM must undergo an adequate surgical resection of the primary lesion; patients must be registered within 49 days (7 weeks) of the surgery.
  • Patients must have available and be willing to submit a minimum of five unstained slides tumor tissue specimens from the GBM surgery or open biopsy for MGMT status analysis and molecular profile analysis.
  • ECOG performance status within 0 - 2
  • Full recovery (< grade 1) from the adverse events associated with prior surgery or any earlier intervention and a minimum of 28 days from the administration of any investigational agent
  • Adequate renal, liver and bone marrow function: Leukocytes >3,000/mcL; Absolute neutrophil count >1,500/mcL; Platelets >100,000/mcL; AST / ALT (SGPT) <2.5 x ULN; Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (except Gilbert's Syndrome, who must have a total bilirubin < 3.0 mg/dL); Creatinine within normal limits
  • Patients must be ≥ 18 years of age
  • Patients must be willing to have blood draws for PK analysis
  • All patients must have a CT or MRI of the brain within 14 days prior to registration. The brain CT or MRI should be performed with intravenous contrast (unless contraindicated).
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines.
  • Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and progression-free survival evaluation;
  • Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment
  • Male patient agrees to use an adequate method of contraception
  • Birth control should be used from the signing of the patient consent form and for 120 days following the last dose of study treatment.
  • In addition, men must not donate sperm during study therapy and for 120 days after receiving the last dose of study treatment.

Exclusion Criteria:

  • Second primary malignancy (except adequately treated basal cell carcinoma of the skin).
  • Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible
  • Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
  • Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study
  • Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min)
  • Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.
  • Screening ECG abnormality documented by the investigator as medically significant
  • Inability to comply with protocol or study procedures.
  • Women who are pregnant or breastfeeding.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: OKN-007 3 days per week plus temozolomide

OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions

400 mg OKN-007/mL in a phosphate buffer

75 mg/m2

standard of care treatment to be given 1 to 2 hours after OKN-007

Eksperimentel: OKN-007 5 days per week and temozolomide

OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions

400 mg OKN-007/mL in a phosphate buffer

75 mg/m2

standard of care treatment to be given 1 to 2 hours after OKN-007

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The maximum tolerated dose and the type of dose limiting toxicities
Tidsramme: 5 years

To determine how well patients are able to tolerate combination of OKN-007, temozolomide, and radiotherapy. Adverse events will be tabulated using MedDRA. The severity of the AE will be graded by the Investigator using the NCI CTCAE, version 4.03.

5 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants who experience progression-free survival
Tidsramme: 5 years

To evaluate the proportion of patients who receive combination OKN-007 and TMZ who do not experience progression

5 years
Number of participants who comply with study treatment plan
Tidsramme: 5 years

To evaluate the clinical compliance of participants receiving combination OKN-007 and TMZ

5 years
Number of participants who are able to receive a reduction in steroid dose
Tidsramme: 5 years

To evaluate whether study drug combination allows for a reduced steroid dosage

5 years
Number of participants who experience overall survival
Tidsramme: 5 years

To evaluate the proportion of patients who receive combination OKN-007 and TMZ who experience overall survival

5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: James Battiste, MD, Principal Investigator

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. september 2018

Primær færdiggørelse (Faktiske)

23. december 2020

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

4. juni 2018

Først indsendt, der opfyldte QC-kriterier

12. juli 2018

Først opslået (Faktiske)

16. juli 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • OU-SCC-Oblato-001
  • OKN-007 (Andet bevillings-/finansieringsnummer: Oblato Inc)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .